Novo Nordisk has expanded its partnership with Valo Health to leverage AI for drug discovery, focusing on treatments for cardiometabolic diseases. Simultaneously, AMD is investing $20 million in Absci to enhance its AI capabilities in drug development, aiming to compete with Nvidia. Both companies emphasize the importance of integrating AI with human data to advance drug discovery, signaling a shift from traditional lab methods to AI-driven processes in the biotech industry.